Labiotech.eu

News and Trends 24 Oct 2016

Here comes the First-ever Combination Therapy for Multiple Sclerosis

Actelion is overcoming the upcoming expiration of one of its most profitable patents and it’s using its strong position to make the leap into the crowded market of multiple sclerosis with the first-ever combination therapy. Actelion is one of the top billion-euro Biotechs in Europe and a leader in pulmonary arterial hypertension (PAH). Although the patent for […]

October 24, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 24 Oct 2016

The Colours of Biotech: Who’s Doing What in the European Ecosystem in an Infographic

Happy Monday! Our colleague, Justine, has put together a wonderful infographic to map out which European biotech companies are making moves in which field, from health to agrotech to medtech. Its vivid colours will surely brighten your day – take a look-see below! Justine is pursuing a PhD at the Heinrich Heine Universität in Düsseldorf after obtaining […]

October 24, 2016 - 1 minutemin - By Evelyn Warner

The Growing Lab Mycelia ©Officina Corpuscoli Maurizio Montalti pure mycelium pattern2 e1477066281946

News and Trends 22 Oct 2016

Meet the Bioartist that wants to Replace all your Furniture with… Fungi!

Can you imagine a future where everything in your daily life is made out of fungi..? It’s actually not such a stretch idea: this bioartist is showing the world all these microorganisms can do. Maurizio Montalti is an artist that uses fungi to build his own furniture and homeware. In 2010, he founded Officina Corpuscoli in Amsterdam […]

October 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 10 21 at 12.29.43 PM e1477045913351

News and Trends 21 Oct 2016

New Partnership comes to the Rescue in Neurological Diseases

Developing effective treatments for neurological diseases is a big challenge in medicine. But here come UCB and Evotec with a new partnership that could help those suffering from epilepsy and Parkinson’s. UCB is a Biotech from Brussels that focuses on neurological and immune diseases. The company has multiple products on the market, including an antibody drug for arthritis and […]

October 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 10 20 at 6.49.20 PM e1476982237695

News and Trends 21 Oct 2016

It’s time to Modernize Anesthetics! Meet the PAIONeers

We travel from Finland back to the heart of Europe to visit the beautiful sights of Aachen. The citizens are starting to turn on the heat and get ready for its famous Christmas markets, while we visit our Biotech of the week, Paion. City: Aachen, Germany Founded: 2000 Employees: 35 Financial Data: €163M market cap + €10M in […]

October 21, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 21 Oct 2016

Mallorca’s not just for Holidays: Sanifit starts Phase II in a Rare Disease

Forget about Madrid and Barcelona, the island of Mallorca has one of the hottest Biotechs in Spain: Sanifit is targeting calciphylaxis, an orphan disease that affects the huge dialysis market. Sanifit received the highest financing round in Spain last year (and probably ever) with €36.6M in series C. With this money, the company is advancing its candidate SNF472 in […]

October 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Oct 2016

German Record-deal Antiviral drug Succeeds in Phase III

AiCuris’ Letermovir succeeds in Phase III after being licensed to MSD in a record €442.5M deal. It acts on a novel CMV target to treat bone marrow transplant infections. AiCuris is a spin-out company from Bayer, Germany’s biggest Pharma, that focuses on developing drugs for infectious diseases. The company licensed its candidate Letermovir (AIC246) to MSD (Merck & co.) in 2012, making it the […]

October 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Oct 2016

CRISPR Thx’ surprisingly low IPO… why are Investors Discouraged?

Troubled waters in the CRISPR field: CRISPR Therapeutics’ IPO hits an unexpectedly low price. It seems that the investors are starting to switch from hype to uncertainty, but why now? CRISPR Therapeutics has just announced the results of a surprisingly low IPO: €51M ($56M), way lower than its €80M target. Its competitors in the therapeutics CRISPR field, Editas […]

October 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Oct 2016

Planning a Clinical Trial? Here’s why Data Management matters

Data from therapy development, especially those involving cells, can quickly mushroom into an unmanageable pile in the lab — what happens when you move to the clinic? We sat down with Venn Life Sciences to discuss effective strategies in data management that might benefit companies looking to bring a therapy like Tregs to market. Cell […]

October 20, 2016 - 4 minutesmins - By External Contributor

News and Trends 19 Oct 2016

The ‘First and Only’ Metastatic Lung Cancer Immunotherapy is approved

Roche’s Genentech has received FDA approval for an immunotherapy targeting the highly sought-after PD-L1. The treatment may be able to outperform its competitors in lung cancer therapies. In May, Roche received approval for Tecentriq (atezolizumab) in bladder cancer. Now, the drug is expanding its indications to become the first and only cancer immunotherapy in the market to target […]

October 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Oct 2016

And the highest funding in Europe this year goes to… Antibody-Drug Conjugates!

AstraZeneca has contributed to ADC Therapeutics’ €96M fundraising, the biggest round so far in Europe this year. Will this huge investment pay out for the British-Swedish Big Pharma? ADC Therapeutics (ADCT) is a Swiss Biotech that develops antibody-drug conjugates (ADCs) for oncology applications. Its founder Auven Therapeutics and its partner AstraZeneca have participated in the biggest […]

October 19, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Oct 2016

This Technology Opens new Horizons for Protein Production

Based in Cologne, Germany, Cevec focuses on human cell-based expression system for production of biological therapies. We’ve already covered their breakthroughs for safer gene therapy and the potential of CAP-GT for expression of viral vectors. Besides CAP-GT, CEVEC has also developed a cell line that can produce complex glycosylated proteins. A good example of glycosylated protein is […]

October 19, 2016 - 5 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Here comes the First-ever Combination Therapy for Multiple Sclerosis

The Colours of Biotech: Who’s Doing What in the European Ecosystem in an Infographic

Meet the Bioartist that wants to Replace all your Furniture with… Fungi!

New Partnership comes to the Rescue in Neurological Diseases

It’s time to Modernize Anesthetics! Meet the PAIONeers

Mallorca’s not just for Holidays: Sanifit starts Phase II in a Rare Disease

German Record-deal Antiviral drug Succeeds in Phase III

CRISPR Thx’ surprisingly low IPO… why are Investors Discouraged?

Planning a Clinical Trial? Here’s why Data Management matters

The ‘First and Only’ Metastatic Lung Cancer Immunotherapy is approved

And the highest funding in Europe this year goes to… Antibody-Drug Conjugates!

This Technology Opens new Horizons for Protein Production

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!